The 7 AML patients enrolled on the study all expressed at least one NKG2D-ligand in the AML blast population, however the mean fluorescence intensity (MFI) of expression was low and no comprehensive studies to assess the preclinical efficacy of NKG2D-CAR T cells in AML or T-ALL have been conducted. The gene discussed is KLRK1; the disease is acute lymphoblastic leukemia.